Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 2/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | LDHB | P07195 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547680 | 0.80 | PDE2A (0.35) | TEAD1CYP26A1AKR1C3AKR1C2PDE2A | |
| SCHEMBL2547677 | 0.80 | PDE2A (0.35) | TEAD1CYP26A1AKR1C3AKR1C2PDE2A | |
| SCHEMBL2548062 | 0.80 | CES2 (0.32) | TEAD1CYP26A1AKR1C3AKR1C2SLC6A9 | |
| SCHEMBL4839775 | 0.79 | TEAD1 (0.37) | TEAD1CYP26A1AKR1C3AKR1C2MLYCD | |
| SCHEMBL1596367 | 0.79 | AKR1C3 (0.33) | AKR1C3AKR1C2PDE2ASLC6A9 | |
| SCHEMBL12241678 | 0.76 | JAK3 (0.36) | TEAD1CYP26A1PDE2A | |
| SCHEMBL2544118 | 0.75 | GRM8 (0.33) | TEAD1SLC6A9 | |
| SCHEMBL2549433 | 0.73 | GRM8 (0.32) | SLC6A9 | |
| SCHEMBL5018934 | 0.72 | AKR1C3 (0.39) | TEAD1CYP26A1AKR1C3AKR1C2PDE2A | |
| SCHEMBL1595193 | 0.72 | SLC1A3 (0.40) | CYP26A1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | TEAD1 1685/4885CYP26A1 3626/4885AKR1C3 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.